SCHEMBL3827809

SCHEMBL3827809

C=C/C=C/CCCCCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.63
MAPT P10636 4/20 0.63
ABCC4 O15439 1/20 0.63
TERT O14746 3/20 0.57
PTPN1 P18031 3/20 0.57
PPARG P37231 3/20 0.57
PPARD Q03181 3/20 0.57
PPARA Q07869 3/20 0.57
F7 P08709 3/20 0.57
F3 P13726 3/20 0.57
BLM P54132 2/20 0.57
HSD17B10 Q99714 2/20 0.57
FABP4 P15090 2/20 0.57
DUSP3 P51452 2/20 0.57
PTPN7 P35236 2/20 0.57
GMNN O75496 1/20 0.57
USP2 O75604 1/20 0.57
LMNA P02545 1/20 0.57
CYP1A2 P05177 1/20 0.57
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28905639 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL28717295 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL10476863 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL5792039 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL2573674 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL10476864 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL28720703 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL2571576 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL2571577 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1
SCHEMBL28717374 1.00 FASN (0.63) FASNMAPTABCC4TERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466917-B1 METHOD FOR PREPARING (7E)- 7,9-DECADIENOATE ESTER SHINETSU CHEMICAL CO (JP) 2020-06-24 EP claimed
EP-1268930-B1 Method for making a coating composition BASF SE (DE) 2009-09-09 EP claimed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
WO-2023213310-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2023-11-09 WO disclosed
CN-115607677-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2023-01-17 CN disclosed
CN-109627162-B Process for preparing (7E) -7, 9-decanedioic acid esters 信越化学工业株式会社 2022-11-15 CN disclosed
CN-114788872-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2022-07-26 CN disclosed
CN-114569726-A Compound for preventing, preventing or treating microbial infection and preparation method and application thereof 太阳雨林(北京)生物医药有限公司 2022-06-03 CN disclosed
CN-114380689-A Haloalkenylalkoxymethyl ethers and processes for preparing terminally conjugated alkadien-1-yl acetates and alkadien-1-ols therefrom 信越化学工业株式会社 2022-04-22 CN disclosed
EP-3466917-B1 METHOD FOR PREPARING (7E)- 7,9-DECADIENOATE ESTER SHINETSU CHEMICAL CO (JP) 2020-06-24 EP disclosed
US-20200155575-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2020-05-21 US disclosed
US-20190106374-A1 METHOD FOR PREPARING (7E)-7, 9-DECADIENOATE ESTER SHIN-ETSU CHEMICAL CO., LTD. (JP) 2019-04-11 US disclosed
EP-3466917-A1 METHOD FOR PREPARING (7E)- 7,9-DECADIENOATE ESTER Shin-Etsu Chemical Co., Ltd. (JP) 2019-04-10 EP disclosed
US-20180104257-A1 (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use LIPOCINE INC. (US) 2018-04-19 US disclosed
US-20180078568-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2018-03-22 US disclosed
EP-3185873-A1 PHARMACEUTICAL COMPOSITION AND METHODS Lipocine Inc. (US) 2017-07-05 EP disclosed
US-20160193225-A1 (17-ß)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE LIPOCINE INC. (US) 2016-07-07 US disclosed
US-20160184324-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2016-06-30 US disclosed
WO-2016033611-A1 (17-β)-3-OXOANDROST-4-EN-17-YL UNDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE LIPOCINE INC. (US) 2016-03-03 WO disclosed
WO-2016033536-A1 PHARMACEUTICAL COMPOSITION AND METHODS LIPOCINE INC. (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106374-A1 METHOD FOR PREPARING (7E)-7, 9-DECADIENOATE ESTER DHCR7, DECR1, CYP7A1 FASN 990/4885MAPT 4874/4885ABCC4 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.